pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,557 catalysts · 3,350 8k filing · 577 earnings · 203 grant · 172 phase 2 completion · 163 approval · 133 drug shortage

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 0 catalysts2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2026-04-06×clear all
type
  • 8k filing3,350
  • earnings577
  • grant203
  • phase 2 completion172
  • approval163
  • drug shortage133
device 510k
81
  • phase 1 completion73
  • phase 2 initiation62
  • recall52
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 28, 20268k filing111d ago$PASG — Passage BIO, Inc. (PASG) — 8-K filing

    Items: 2.05

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$ACRS — Aclaris Therapeutics, Inc. (ACRS) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$INCY — INCYTE CORP (INCY) — 8-K filing

    Items: 2.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$AVTX — Avalo Therapeutics, Inc. (AVTX) — 8-K filing

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$IMUX — IMMUNIC, INC. (IMUX) — 8-K filing

    Items: 5.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$SGMT — Sagimet Biosciences Inc. (SGMT) — 8-K filing

    Items: 1.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$ELAB — PMGC Holdings Inc. (ELAB) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$KNSA — Kiniksa Pharmaceuticals International, plc (KNSA) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$WVE — Wave Life Sciences Ltd. (WVE) — 8-K filing

    Items: 2.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d agoROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) — 8-K filing

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$SNGX — SOLIGENIX, INC. (SNGX) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$BCDA — BioCardia, Inc. (BCDA) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$ALLR — Allarity Therapeutics, Inc. (ALLR) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d agoSilexion Therapeutics Corp (SLXN, SLXNW) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$BMEA — Biomea Fusion, Inc. (BMEA) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$ARAY — ACCURAY INC (ARAY) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$CLYM — Climb Bio, Inc. (CLYM) — 8-K filing

    Items: 1.01, 3.02, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$GILD — GILEAD SCIENCES, INC. (GILD) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$ACET — Adicet Bio, Inc. (ACET) — 8-K filing

    Items: 3.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$NRC — NRC HEALTH (NRC) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$ACLX — Arcellx, Inc. (ACLX) — 8-K filing

    Items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$DSGN — Design Therapeutics, Inc. (DSGN) — 8-K filing

    Items: 2.02, 7.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$NRC — NRC HEALTH (NRC) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$OPK — OPKO HEALTH, INC. (OPK) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$VTGN — Vistagen Therapeutics, Inc. (VTGN) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$LABT — Lakewood-Amedex Biotherapeutics Inc. (LABT) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d agoSeaStar Medical Holding Corp (ICU, ICUCW) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$FLNA — FILANA THERAPEUTICS, INC. (FLNA) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$PTCT — PTC THERAPEUTICS, INC. (PTCT) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$HRGN — Harvard Apparatus Regenerative Technology, Inc. (HRGN) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$MDGL — MADRIGAL PHARMACEUTICALS, INC. (MDGL) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$FENC — FENNEC PHARMACEUTICALS INC. (FENC) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$QNCX — Quince Therapeutics, Inc. (QNCX) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$PREM — Premier Air Charter Holdings Inc. (PREM) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d agoScilex Holding Co (SCLX, SCLXW) — 8-K filing

    Items: 1.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$JANX — Janux Therapeutics, Inc. (JANX) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$CTOR — CITIUS ONCOLOGY, INC. (CTOR) — 8-K filing

    Items: 3.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$QUCY — Quantum Cyber N.V. (QUCY) — 8-K filing

    Items: 1.01, 3.02, 5.01, 5.02, 5.03, 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$GRDX — GridAI Technologies Corp. (GRDX) — 8-K filing

    Items: 3.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing111d ago$LNAI — Lunai Bioworks Inc. (LNAI) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 2026pdufa110d agoSanofi — teplizumab (PDUFA)teplizumab

    Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

    full page →teplizumab →source: globaldata
    ›Apr 29, 2026phase 0 trial completion110d agoDana-Farber Cancer Institute Inc — atezolizumab (Phase 0 Trial Completion)atezolizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer

    full page →atezolizumab →source: globaldata
    ›Apr 29, 2026phase 1 completion110d agoBoehringer Ingelheim International GmbH — BI-765179 (Phase I Trial Completion)BI-765179

    Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re

    full page →BI-765179 →source: globaldata
    ›Apr 29, 2026phase 1 completion110d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 completion110d agoAltasciences Co Inc — NN-7442 (Phase I Trial Completion)NN-7442

    Therapy area: Hematological Disorders. Indication: Hemophilia A (Factor VIII Deficiency)

    full page →NN-7442 →source: globaldata
    ›Apr 29, 2026phase 1 initiation110d agoTerSera Therapeutics LLC — goserelin LA (Phase I Trial Initiation)goserelin LA

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →goserelin LA →source: globaldata
    ›Apr 29, 2026phase 1 initiation110d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ›Apr 29, 2026phase 1 initiation110d agoAgios Pharmaceuticals Inc — AG-181 (Phase I Trial Initiation)AG-181

    Therapy area: Metabolic Disorders. Indication: Phenylketonuria (PKU)

    full page →AG-181 →source: globaldata
    ›Apr 29, 2026phase 1 initiation110d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 29, 2026phase 2 completion110d agoCARsgen Therapeutics Holdings Ltd — CT-0594CP CAR-T Cells (Phase II Trial Completion)CT-0594CP CAR-T Cells

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →CT-0594CP CAR-T Cells →source: globaldata
    ← prev
    page 21 of 92
    next →
    $OCGN1.2800-2.29%
    $SNY43.72-0.14%
    $AGIO33.56+0.27%